Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Cash resources are expected to support planned operations into the second half of 2028, beyond the anticipated 2027 clinical readout.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Taysha Gene Therapies (TSHA) reported a third-quarter 2026 net loss of $39.1 million while advancing its TSHA-102 Rett syndrome program. Loss per share was $0.10, versus $0.09 a year earlier, when net loss was $32.7 million. Cash and equivalents totaled $422.8 million at September 30; the company expects funding into the second half of 2028.
Across the REVEAL Phase 1/2, pivotal and ASPIRE trials, no severe treatment-related serious adverse events or dose-limiting toxicities were observed in 33 patients through the November 2026 cutoff. Taysha completed its commercial-scale manufacturing validation campaign, meeting product specifications and comparability criteria. The company expects six-month pivotal interim results and FDA feedback on the biologics license application pathway in the first half of 2027. It also expects to nominate another gene therapy candidate and begin preclinical development in that period.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointCash and equivalents rose to $422.834 million at September 30, 2026, from $319.767 million at December 31, 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway is expected to cover planned operating expenses and capital requirements into the second half of 2028.
- Moderate point33 TSHA-102 patients had no severe treatment-related serious adverse events or dose-limiting toxicities through the November 2026 cutoff.
- Moderate pointManufacturing validation campaign completed, with commercial-scale batches meeting predefined product specifications and commercial/clinical material comparability criteria.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Six-month pivotal interim results are expected in the first half of 2027.
5 minor points
- Minor pointAll treated patients cleared acute post-dosing safety monitoring across REVEAL Phase 1/2, pivotal and ASPIRE trials.
- Minor point. Forward-looking: it has not happened yet and may not happen.Manufacturing comparability results support potential inclusion of REVEAL Part A data in the planned biologics license application.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional gene therapy candidate nomination and preclinical development are expected in the first half of 2027.
- Minor pointNine-month lease termination gain was $3.433 million, versus none in the comparable 2025 period.
- Minor pointTotal liabilities declined to $78.058 million at September 30, 2026, from $96.382 million at December 31, 2025.
Negative
- Moderate pointThird-quarter net loss widened to $39.128 million, or $0.10 per share, from $32.733 million, or $0.09.
- Moderate pointNine-month net loss widened to $128.177 million, or $0.34 per share, from $81.144 million, or $0.26.
- Moderate pointCommon shares outstanding increased to 325,883,280 at September 30, 2026, from 285,051,648 at December 31, 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.FDA pathway feedback remains pending, with feedback on the biologics license application submission pathway expected in the first half of 2027.
- Minor pointThird-quarter research and development expenses rose to $28.766 million from $25.745 million a year earlier.
4 minor points
- Minor pointThird-quarter administrative expenses rose to $13.106 million from $8.279 million a year earlier.
- Minor pointNine-month revenue fell to zero in 2026 from $4.288 million in 2025.
- Minor pointNine-month research and development expenses increased to $101.211 million from $61.451 million a year earlier.
- Minor pointNine-month administrative expenses increased to $34.929 million from $25.035 million a year earlier.
News Explained
At September 30, Taysha reported 325,883,280 common shares outstanding, up from 285,051,648 at December 31, 2025; for holders keeping the same number of shares, the larger total means a smaller proportional ownership stake.
Key Figures
- Research and development expenses
- $28.8 million vs. $25.7 million
- Three months ended September 30, 2026 vs. 2025
- General and administrative expenses
- $13.1 million vs. $8.3 million
- Three months ended September 30, 2026 vs. 2025
- Net loss
- $39.1 million, or $0.10 per share, vs. $32.7 million, or $0.09 per share
- Three months ended September 30, 2026 vs. 2025
- Cash and cash equivalents
- $422.8 million
- As of September 30, 2026
- Cash runway
- Into the second half of 2028
- Company expectation for planned operating expenses and capital requirements
- Patients treated
- 33 patients; no severe treatment-related SAEs or DLTs
- TSHA-102 trials as of the November 2026 data cutoff
- Empty capsid percentage
- Single-digit percentage
- TSHA-102 commercial manufacturing process
- Interim data and FDA feedback
- First half of 2027
- Expected REVEAL pivotal six-month interim data and BLA pathway feedback
Previous Earnings Reports
-
Reported widening quarterly loss, 33-patient TSHA-102 safety, and PPQ completion expected in Q4.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adeno-associated virus (aav) medical
biologics license application (bla) regulatory
process performance qualification (ppq) technical
serious adverse events (saes) medical
dose limiting toxicities (dlts) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027
TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff
Completed BLA-enabling PPQ manufacturing campaign for TSHA-102, which met predefined product specifications as well as comparability criteria for commercial product and clinical material, supporting potential inclusion of REVEAL Part A Phase 1/2 data in the planned BLA
Encore data supporting TSHA-102 clinical program presented at the 55th Child Neurology Society Annual Meeting
Conference call and webcast today at 8:30 AM ET
DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.
“During the third quarter, we continued to make strong progress across our clinical, manufacturing and commercial readiness activities as we advance toward a potential BLA submission for TSHA-102,” said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. “With all patients dosed and having cleared the acute post-dosing safety monitoring period in our REVEAL pivotal and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed across all studies, our focus now turns to delivering a robust dataset to support our planned BLA submission and further establish the potential of TSHA-102 to address the significant unmet need in Rett syndrome. In parallel, we achieved an important manufacturing milestone with the successful completion of our BLA-enabling PPQ manufacturing campaign, which met the predefined acceptance and comparability criteria previously reviewed with FDA. Importantly, the results further demonstrated our ability to consistently manufacture high-quality product at commercial scale, including an encouraging single-digit empty capsid percentage, a key indicator of product quality that contributes to patient safety. Looking ahead, we believe the first half of 2027 could be a transformative period for Taysha with our plan to report data from the six-month interim analysis of our REVEAL pivotal trial along with expected FDA feedback on our BLA submission pathway, and the anticipated nomination of a second gene therapy development program with a high unmet medical need and robust commercial opportunity as we begin building a broader CNS genetic medicine franchise.”
Recent Corporate and TSHA-102 Program Highlights
- REVEAL Pivotal and ASPIRE Trials Ongoing with TSHA-102 Continued to be Generally Well-Tolerated. High dose (1x1015 total vector genomes (vg)) and low dose (5.7x1014 total vg) TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff. All patients in the REVEAL Phase 1/2 (n=12), pivotal (n=17) and ASPIRE (n=4) trials have cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies with no dose-limiting toxicities observed across all trials.
- Completed BLA-Enabling Process Performance Qualification (PPQ) Campaign for TSHA-102. Following alignment on the company’s proposed PPQ strategy with the U.S. Food and Drug Administration (FDA), Taysha completed its Biologics License Application (BLA)-enabling PPQ manufacturing campaign for TSHA-102, including the successful production of commercial-scale drug product batches required to validate the final commercial manufacturing process in support of a potential BLA submission and future commercialization of TSHA-102.
- All process parameters and analytical results met predefined product specifications as well as comparability criteria for commercial product and clinical material. Together with the comparability of the clinical material used across the REVEAL Part A and Part B pivotal trials, these results support the potential inclusion of REVEAL Part A data in the planned BLA submission.
- The final TSHA-102 commercial manufacturing process consistently achieved a single-digit empty capsid percentage, an important indicator of product quality that contributes to patient safety. The PPQ results also demonstrate the process consistency and scalability required to support potential commercial demand. The Company plans to discuss these Chemistry Manufacturing and Controls (CMC) data in an anticipated meeting with FDA in the fourth quarter of 2026 to further strengthen the CMC package for the potential BLA submission.
- Showcased Multiple Encore Presentations Supporting TSHA-102 Clinical Program at the 55th Child Neurology Society Annual Meeting. One oral presentation and three poster presentations were delivered at the 55th Child Neurology Society Annual Meeting. The presentations, available on the Company’s website, highlighted data previously presented at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting.
Anticipated Milestones
- FDA feedback following CMC Type B meeting expected in the first quarter of 2027
- Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027
- Expect to nominate an additional gene therapy development candidate targeting a CNS disorder with high unmet need and commence preclinical development activities in the first half of 2027
Third Quarter 2026 Financial Highlights
Research and Development Expenses: Research and development expenses were
General and Administrative Expenses: General and administrative expenses were
Net Loss: Net loss for the three months ended September 30, 2026, was
Cash and Cash Equivalents: As of September 30, 2026, Taysha had
Conference Call and Webcast Information
Taysha management will host a live conference call and webcast today at 8:30 a.m. ET to review its financial and operating results and provide a corporate update. Participants may access the live webcast of the conference call by visiting Taysha’s website.
About TSHA-102
TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.
About Rett Syndrome
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning the potential of TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development, regulatory and manufacturing plans for its product candidates, communications with the FDA, including with respect to the BLA for TSHA-102, the potential for Taysha’s product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed and the potential market opportunity for Taysha’s product candidates, Taysha’s manufacturing and commercial readiness activities, Taysha’s anticipated nomination of a second gene therapy development program with a high unmet medical need and strong commercial opportunity, and the ability of Taysha’s current cash resources to support planned operating expenses into the second half of 2028. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in Taysha’s Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.
| Taysha Gene Therapies, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | — | $ | — | $ | — | $ | 4,288 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 28,766 | 25,745 | 101,211 | 61,451 | ||||||||||||
| General and administrative | 13,106 | 8,279 | 34,929 | 25,035 | ||||||||||||
| Net gain on lease termination | — | — | (3,433 | ) | — | |||||||||||
| Total operating expenses | 41,872 | 34,024 | 132,707 | 86,486 | ||||||||||||
| Loss from operations | (41,872 | ) | (34,024 | ) | (132,707 | ) | (82,198 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Change in fair value of warrant liability | — | (292 | ) | — | (463 | ) | ||||||||||
| Change in fair value of term loan | (1,087 | ) | (1,534 | ) | (4,078 | ) | (4,525 | ) | ||||||||
| Interest income | 3,903 | 3,169 | 8,814 | 6,354 | ||||||||||||
| Interest expense | (4 | ) | (15 | ) | (19 | ) | (51 | ) | ||||||||
| Other expense | (68 | ) | (37 | ) | (187 | ) | (261 | ) | ||||||||
| Total other income (expense), net | 2,744 | 1,291 | 4,530 | 1,054 | ||||||||||||
| Net loss | $ | (39,128 | ) | $ | (32,733 | ) | $ | (128,177 | ) | $ | (81,144 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.10 | ) | $ | (0.09 | ) | $ | (0.34 | ) | $ | (0.26 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 406,106,872 | 353,309,524 | 380,739,173 | 307,175,982 | ||||||||||||
| Taysha Gene Therapies, Inc. Condensed Consolidated Balance Sheet Data (in thousands, except share and per share data) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 422,834 | $ | 319,767 | ||||
| Restricted cash | — | 449 | ||||||
| Prepaid expenses and other current assets | 3,221 | 4,431 | ||||||
| Total current assets | 426,055 | 324,647 | ||||||
| Restricted cash | 165 | 2,315 | ||||||
| Property, plant and equipment, net | 2,526 | 6,736 | ||||||
| Operating lease right-of-use assets | 6,236 | 9,439 | ||||||
| Other non-current assets | 48 | 183 | ||||||
| Total assets | $ | 435,030 | $ | 343,320 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 5,592 | $ | 6,275 | ||||
| Accrued expenses and other current liabilities | 17,358 | 20,277 | ||||||
| Total current liabilities | 22,950 | 26,552 | ||||||
| Term loan, net | 47,331 | 50,106 | ||||||
| Operating lease liability, net of current portion | 6,104 | 18,172 | ||||||
| Other non-current liabilities | 1,673 | 1,552 | ||||||
| Total liabilities | 78,058 | 96,382 | ||||||
| Commitments and contingencies - Note 13 | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 3 | 3 | ||||||
| Additional paid-in capital | 1,194,098 | 958,427 | ||||||
| Accumulated other comprehensive income (loss) | 2,348 | (192 | ) | |||||
| Accumulated deficit | (839,477 | ) | (711,300 | ) | ||||
| Total stockholders’ equity | 356,972 | 246,938 | ||||||
| Total liabilities and stockholders' equity | $ | 435,030 | $ | 343,320 | ||||
Company Contact:
investors@tayshagtx.com
Media Contact:
Media@tayshagtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Taysha expect TSHA-102 pivotal trial results?
Taysha expects topline results from the REVEAL pivotal trial six-month interim analysis in the first half of 2027. FDA feedback on the biologics license application submission pathway is also expected in that period.
How long does Taysha expect its cash to last?
Taysha expects its current cash resources to support planned operating expenses and capital requirements into the second half of 2028. Cash and cash equivalents were $422.8 million at September 30, 2026.
When will Taysha discuss TSHA-102 manufacturing data with the FDA?
Taysha plans to discuss its chemistry, manufacturing and controls data with the FDA at an anticipated meeting in the fourth quarter of 2026. Feedback following the manufacturing-focused Type B meeting is expected in the first quarter of 2027.